-
Diagnostics World News | Illumina today announced an investment and collaboration into MyOme, a genomics and risk modeling company. The collaboration and investment will help advance MyOme’s Proactive Health (MPH) Trial—a clinical trial seeking to quantify the cost savings and improved patient outcomes for whole-genome sequencing (WGS) combined with MyOme’s AI-integrated risk models (IRMs)—and help expand MyOme’s suite of proactive health and rare disease diagnostic tests. Neither financial details nor milestones of the investment were disclosed.
Dec 11, 2025
-
Diagnostics World News | Thanks to promising developments in psychedelic and dissociative compounds, treatments for depression are likely to significantly change in the next 10 years. However, psychedelics also come with their own set of complications and side effects, such as disconnection from oneself and one’s surroundings and cardiovascular changes.
Dec 10, 2025
-
Diagnostics World News | Oxford Nanopore Technologies named a new CEO this morning, choosing an executive with extensive diagnostics experience. Francis Van Parys, currently CEO of Radiometer, will join Oxford Nanopore and the Board as an Executive Director on March 2, 2026.
Dec 8, 2025
-
Diagnostics World | When SpaceX’s Inspiration4 lifted off in 2021, it launched new opportunities for commercial space travel and raised new questions about how a space environment impacts the human body. TrialX believes what we learn about biology in space will not only expand our understanding of extreme environments’ impact on human health but will deepen our understanding of how biomarkers and health data are best gathered and explored at home as well.
Dec 4, 2025
-
Diagnostics World | Increasing use of genetic testing to identify people at risk for various diseases has led to a skyrocketing number of never-before-seen variants with uncertain connections to those health conditions, making them impractical to investigate one by one as they once were. Clever bench scientists therefore began making all possible variants in genes with a suspected link to a disease or a patient's symptoms about 15 years ago, to determine which ones are most likely pathogenic.
Dec 2, 2025
-
Diagnostics World | Baylor College of Medicine will continue to create customized cell, fly, and mouse models to study rare genetic diseases; Curve Biosciences will advance the clinical validation and commercialization of their Whole-Body Intelligence platform for chronic disease monitoring; and more.
Nov 25, 2025
-
Diagnostics World | Royal Philips extended their partnership with Cortechs.ai; OCEAN Dx completes a clinical evaluation study for its innovative rapid diagnostic test for sepsis; Nucleai and the University of Glasgow announce a collaboration; and more.
Nov 24, 2025
-
Diagnostics World | Watchmaker Genomics has launched TAPS+, a next-generation technology that unites genetic and epigenetic readouts from the same DNA molecule. By capturing multiple biological dimensions in a single assay, TAPS+ delivers a richer, more comprehensive view of tumor biology, with the power to advance applications in translational oncology, early cancer detection, therapy response monitoring, fragmentomics, and minimal residual disease assessment.
Nov 19, 2025
-
Diagnostics World | The Association for Molecular Pathology hosted its 2025 Annual Meeting & Expo last week. Highlights from some of the research presented at the event include faster molecular tests for dangerous regional fungal infections, new Lyme disease tests, AI tools for improving molecular diagnosis, new use for old DNA samples to understand the evolution of colorectal cancer, and more.
Nov 18, 2025
-
Diagnostics World | In a study published this week in Nature, researchers from Illumina and The University of Queensland demonstrated the importance of whole-genome sequencing (WGS) to more fully capture the genetics underlying complex human traits and diseases.
Nov 14, 2025
-
Diagnostics World | Even though roughly two-thirds of pivotal studies leading to FDA drug approvals now enroll women at rates aligned with their disease burden, their inclusion has “plateaued." Diagnostic criteria and disease models remain largely male-centered because they don’t take into account of the biological and hormonal rhythms that shape women’s health across their lives. That diagnostic blind spot reverberates throughout drug development.
Nov 12, 2025
-
Diagnostics World | Veterans of Illumina and Grail launched Hepta, a biotechnology company using transformer-based AI to read the cell-free DNA (cfDNA) epigenome and detect organ-specific signals of chronic disease. Hepta emerged from stealth with $6.7 million in seed funding.
Nov 11, 2025
-
Diagnostics World | For most physicians, concerns about artificial intelligence (AI) continue to outweigh enthusiasm for its potential to improve healthcare decision-making and patient outcomes. Doctors need to understand the reasons behind the predictions of AI tools if they’re expected to use the insights as a starting point for discussing treatment options with their patients.
Nov 6, 2025
-
Diagnostics World | NHS England is trialing a 15-minute blood test that can distinguish between bacterial or viral infections, identifying serious diseases like sepsis or meningitis quickly in children. The study uses the MeMed BV test. From a small serum or venous whole blood sample, the test measures three host-response biomarkers—TRAIL, IP-10, and CRP.
Nov 4, 2025
-
Diagnostics World | When patients are prescribed drugs with a narrow therapeutic window, where the difference between an effective and toxic dose can be frighteningly small, therapeutic drug monitoring is crucial to their safety. Outside of a hospital setting with expensive lab equipment and specialized staff to do the monitoring, things can get dicey.
Oct 30, 2025
-
Diagnostics World | Pangaea launches its next-generation platform; EpiSign launches its Methylation-based Episignature Testing and Reference-based Interpretation & Classification (METRIC); Biodesix signs an expanded partnership agreement with Bio-Rad Laboratories; and more.
Oct 29, 2025
-
Diagnostics World | Kailera Therapeutics advances their obesity portfolio; Trogenix combines cancer cell killing and immune stimulation, delivered via a Trojan Horse approach that reawakens the immune system; and more.
Oct 28, 2025
-
Diagnostics World | Modern healthcare algorithms are trained with large volumes of data and can recognize patterns and correlate them with outcomes. However, there is still the issue of bias against underrepresented groups, even though these algorithms are trained using diverse populations. Researchers from the Icahn School of Medicine at Mount Sinai have developed AEquity, a tool of identification that reduces biases in datasets used to train machine learning algorithms.
Oct 24, 2025
-
Diagnostics World | Earlier this month, MyHeritage announced that they have upgraded their at-home DNA tests to have Whole Genome Sequencing. By utilizing Ultima Genomics’ sequencing technology and processing at the Gene by Gene lab, MyHeritage is the first major commercial DNA testing company to adopt Whole Genome Sequencing at such a massive scale of over one million tests per year.
Oct 22, 2025
-
Diagnostics World | A new diagnostic tool could soon help oncologists identify which tumors are most vulnerable to a class of immunotherapies that target cancer’s sugar-coated surface. Researchers at the UC Irvine School of Medicine have developed a companion diagnostic that measures glycan density in tumor tissue, which could redefine how solid tumors are detected, classified, and treated.
Oct 16, 2025